首页> 外文OA文献 >Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation Results From the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Study

【2h】

Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation Results From the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Study

机译：RE-LY（长期抗凝治疗的随机评估）研究显示，达比加群与华法林相比对阵发性，持续性和永久性心房颤动患者的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Flaker Greg; Ezekowitz Michael; Yusuf Salim; Wallentin Lars; Noack Herbert; Brueckmann Martina; Reilly Paul; Hohnloser Stefan H.; Connolly Stuart;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: Results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study [J] . FlakerG., EzekowitzM., YusufS., Journal of the American College of Cardiology . 2012,第9期

机译：达比加群与华法林相比在阵发性，持续性和永久性房颤患者中的疗效和安全性：RE-LY（长期抗凝治疗的随机化评估）研究的结果
2. Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis" [J] . Hijazi Ziad, Hohnloser Stefan H., Oldgren Jonas, Circulation: An Official Journal of the American Heart Association . 2014,第22期

机译：对有关“达比加群与华法林相比房颤患者基线肾功能的有效性和安全性的信”的答复：RE-LY（长期抗凝治疗的随机评估）试验分析”
3. Letter by Chin et al Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial Analysis" [J] . Chin Paul K. L., Wright Daniel F. B., Florkowski Christopher M. Circulation: An Official Journal of the American Heart Association . 2014,第22期

机译：Chin等人关于文章的信，“达比加群与华法林相比，房颤患者基线肾功能的功效和安全性：RE-LY（长期抗凝治疗的随机评估）试验分析”
4. LONG-TERM EFFICACY OF ANTIARRHYTHMIC DRUG THERAPY AND ITS INFLUENCE TO THE PROGNOSIS IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION [C] . KEN OKUMUR International Congress on Electrocardiology . 2005

机译：抗心律失常药物治疗的长期疗效及其对阵发性心房颤动患者预后的影响
5. Cost effectiveness of warfarin in anticoagulant clinic after introduction of dabigatran for stroke prevention in atrial fibrillation patients in the United States [D] . Alhazami, Mai S. 2015

机译：在美国引入达比加群后预防心房颤动患者中风后华法林在抗凝临床中的成本效益
6. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study [O] . Paolo Verdecchia, Gianpaolo Reboldi, Fabio Angeli, -1

机译：达比加群vs.华法林与房颤患者左室肥厚的关系-长期抗凝治疗（RE-LY）研究的随机评估
7. Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial [O] . Stefan H. Hohnloser, Jonas Oldgren, Sean Yang, 2012

机译：在Re-Ly（长期抗凝治疗的随机评估）试验中，用Dabigatran或Warfarin治疗心房颤动治疗心房颤动的心肌缺血事件

Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation Results From the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Study

著录项

引文网络

相似文献

相关主题

期刊订阅